You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK)子公司新冠疫苗獲臨床試驗批准
阿思達克 11-14 11:03
復星醫藥(02196.HK)公布,控股子公司復星醫藥產業收到國家藥監局關於獲許可的新型冠狀病毒mRNA疫苗BNT162b2用於預防新型冠狀病毒肺炎的臨床試驗批准。

BNT162b2為復星醫藥產業與BioNTech合作引進區域內的第二款針對新型冠狀病毒的mRNA疫苗。目前,分別在美國、德國、阿根廷、巴西、南非和土耳其等國處於III期臨床試驗中,並已獲得美國FDA(美國食品藥品管理局)快速通道審評認證。至今,集團針對該疫苗研發的累計投入約為6,619萬人民幣。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account